Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients.
By M. Look, W. van Putten, M. Duffy, N. Harbeck, I. Christensen, C. Thomssen, R. Kates, F. Spyratos, Mårten Fernö, S. Eppenberger-Castori and 30 more. Journal of the National Cancer Institute, 2002
643 citations recorded by the source corpus.
Subfields: Cancer Research, Molecular Biology, Oncology
View Paper: https://www.semanticscholar.org/paper/59e6e1a21227c178b3949a8bcf60b40c88e2a737
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cancer Research
In Molecular Biology
In Oncology
Citations in the corpus
- Obesity and Cancer: The Role of Dysfunctional Adipose Tissue (2009, background): “Overexpression of PAI-1 has been found in many obesity-related types of cancer and is associated with the progression of breast, endometrial, colorectal, thyroid, renal, and prostate cancer (97-102).”
- Meta-analysis of individual participant data: rationale, conduct, and reporting (2010, background): “Another option is to collaborate with other research groups and agree to pool resources to answer specific clinical questions. For example, members of the receptor and biomarker group within the European Organisation for Research and Treatment of Cancer provided 18 datasets for an individual partici”
- American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. (2007, methodology): “Robertson JF, Jaeger W, Syzmendera JJ, et al: The objective measurement of remission and progression in metastatic breast cancer by use of serum tumour markers: European Group for Serum Tumour Markers in Breast Cancer.”